



## **GENIX PHARMACEUTICALS CORPORATION**

### **Condensed Interim Financial Statements**

For the Three Months ended January 31, 2024 and 2023  
*(Expressed in Canadian Dollars - Unaudited)*

	<b><u>Page</u></b>
Table of Contents	iv
Statements of Financial Position	1
Statements of Comprehensive Loss	2
Statements of Cash Flows	3
Statement of Changes in Equity (Deficiency)	4
Notes to Financial Statements	5-15

**GENIX PHARMACEUTICALS CORPORATION**

Statements of Financial Position

*(Expressed in Canadian dollars)*

	Note	January 31, 2024	October 31, 2023
<b>Assets</b>			
<b>Current assets</b>			
Cash		\$ 9,297	\$ 11,631
Receivables		2,989	1,407
Prepaid expense		65,775	43,403
Inventory	4	161,015	159,113
		<b>239,076</b>	<b>215,554</b>
<b>Non-current assets</b>			
Intellectual property	5	5	5
Website	6	7,619	7,902
		<b>\$ 246,700</b>	<b>\$ 223,461</b>
<b>Liabilities and Equity (Deficiency)</b>			
<b>Current liabilities</b>			
Trade and other payables	7	\$ 295,784	\$ 269,054
Loans from shareholders	8	575,387	511,525
Obligation - current portion	5	571,948	580,243
		<b>1,443,119</b>	<b>1,360,822</b>
<b>Equity</b>			
Share capital	10	9,700,762	9,700,762
Warrants reserve	10	12,730	12,730
Share options reserve	10	1,279,850	1,279,850
Accumulated deficit		(12,189,761)	(12,130,703)
		<b>(1,196,419)</b>	<b>(1,137,361)</b>
		<b>\$ 246,700</b>	<b>\$ 223,461</b>

Corporate Information and Nature and Continuance of Operations (Note 1)  
Subsequent Event (Note 14)

Approved by the Board of Directors on March 26, 2024

<u>Paul Chow</u>	<u>Kevin Bottomley</u>
Director	Director

The accompanying notes are an integral part of these financial statements.

**GENIX PHARMACEUTICALS CORPORATION**  
Condensed Interim Statements of Comprehensive Loss  
*(Expressed in Canadian dollars)*

	Note	Three Months ended January 31,	
		2024	2023
<b>Sales</b>			
Nutraceuticals		\$ 71	\$ 1,582
<b>Total Sales</b>		<b>71</b>	<b>1,582</b>
<b>Cost of Goods Sold</b>			
Nutraceuticals		13	757
<b>Total Cost of Goods Sold</b>		<b>13</b>	<b>757</b>
<b>Gross Profit</b>		<b>\$ 58</b>	<b>\$ 825</b>
<b>Operating expenses</b>			
Amortization	5,6	\$ 283	\$ 135,922
Bank charges and interest expense		260	311
Consulting and management fees	9	14,500	55,250
Depreciation	6	-	2,239
Insurance		13,041	13,355
Interest expense	8,9	-	674
Investor relations		320	-
Marketing		300	-
Office and miscellaneous		3,594	4,538
Professional fees	9	5,000	9,898
Regulatory		6,572	5,821
Rent		3,711	520
		<b>\$ 47,581</b>	<b>\$ 228,528</b>
<b>Loss before other items</b>		<b>(47,523)</b>	<b>(227,703)</b>
<b>Other items</b>			
Foreign exchange gain (loss)		12,066	7,142
Interest on shareholder loans	8	(23,634)	(6,607)
Interest income		33	131
		<b>(11,535)</b>	<b>666</b>
<b>Comprehensive and net loss for the period</b>		<b>\$ (59,058)</b>	<b>\$ (227,037)</b>
<b>Basic and diluted loss per share</b>			
Comprehensive and net loss for the period		<b>(0.00)</b>	<b>(0.00)</b>
<b>Weighted average common shares outstanding</b>		<b>59,224,131</b>	<b>59,224,131</b>

The accompanying notes are an integral part of these financial statements.

**GENIX PHARMACEUTICALS CORPORATION**

Condensed Interim Statements of Cash Flows

*(Expressed in Canadian dollars)*

	<b>Three Months ended January 31,</b>	
	<b>2024</b>	<b>2023</b>
<b>Operating activities</b>		
Net loss for the period	\$ (59,058)	\$ (227,037)
Items not affecting cash and cash equivalents		
Amortization	283	135,922
Depreciation	-	2,239
Interest on office lease	-	98
Interest on shareholder loans	23,634	6,607
Foreign exchange on obligation	(8,295)	(6,107)
Changes in non-cash working capital		
Receivables	(1,582)	7,999
Prepays	(22,372)	(19,699)
Inventory	(1,902)	757
Accounts payable and accrued liabilities	26,730	47,758
Total cash outflows from operating activities	\$ (42,562)	\$ (51,463)
<b>Financing activities</b>		
Repayments of obligation	\$ -	\$ (58,839)
Repayments of lease liability	-	(3,000)
Loans from shareholders	40,228	145,323
Total cash inflows from financing activities	\$ 40,228	\$ 83,484
<b>Net change in cash and cash equivalents</b>	<b>\$ (2,334)</b>	<b>\$ 32,020</b>
Cash, beginning of period	11,631	9,267
<b>Cash, end of period</b>	<b>\$ 9,297</b>	<b>\$ 41,287</b>
<b>Supplemental disclosure:</b>		
Cash paid for interest payments	\$ -	\$ 98

The accompanying notes are an integral part of these financial statements.

**GENIX PHARMACEUTICALS CORPORATION**

Condensed Interim Statements of Changes in Equity (Deficiency)

*(Expressed in Canadian dollars)*

	Note	Number of shares	Share capital	Warrants reserve	Share options reserve	Accumulated deficit	Total
<b>Balance, October 31, 2022</b>		59,224,131	\$ 9,700,762	\$ 12,730	\$ 1,220,640	\$ (7,735,129)	\$ 3,199,003
Net loss for the period		-	-	-	-	(227,037)	(227,037)
<b>Balance, January 31, 2023</b>		59,224,131	\$ 9,700,762	\$ 12,730	\$ 1,220,640	\$ (7,962,166)	\$ 2,971,966
Net loss for the period					\$ 59,210	(4,168,537)	(4,109,327)
<b>Balance, October 31, 2023</b>		<b>59,224,131</b>	<b>9,700,762</b>	<b>12,730</b>	<b>1,279,850</b>	<b>(12,130,703)</b>	<b>(1,137,361)</b>
Net loss for the period		-	-	-	-	(59,058)	(59,058)
<b>Balance, January 31, 2024</b>		<b>59,224,131</b>	<b>\$ 9,700,762</b>	<b>\$ 12,730</b>	<b>\$ 1,279,850</b>	<b>\$ (12,189,761)</b>	<b>\$ (1,196,419)</b>

The accompanying notes are an integral part of these financial statements.

## **GENIX PHARMACEUTICALS CORPORATION**

Notes to Condensed Interim Financial Statements

*(Expressed in Canadian dollars)*

For the three months ended January 31, 2024 and 2022

---

### **1. CORPORATE INFORMATION AND NATURE OF OPERATIONS**

Genix Pharmaceuticals Corporation (formerly Alta Natural Herbs & Supplements Ltd.) (the “Company” or “Genix”) was incorporated under the Alberta Business Corporations Act on July 12, 1993 and is currently a publicly traded company listed on the TSX Venture Exchange under the symbol “GENX” and also trades on the OTCQB® in the United States (OTCQB: GENPF). The Company is a formulator, manufacturer, licensor and marketer of life sciences related products with a focus on nutraceuticals and pharmaceuticals.

The Company’s registered office, principal address and registered and records office is 10022 – 102 Avenue, Grand Prairie, Alberta, T8V 0Z7.

The financial statements were authorized by the Board of Directors on March 26, 2024.

These financial statements have been prepared in accordance with International Financial Reporting Standards with the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business.

These financial statements have been prepared by management on a going concern basis which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The continuing operations of the Company are dependent upon its ability to continue to raise adequate financing and to commence profitable operations in the future. In the event that cash flow from operations, if any, together with the proceeds from any future financings are insufficient to meet the Company’s current operating expenses, the Company will be required to re-evaluate its planned expenditures and allocate its total resources in such a manner as the Board of Directors and management deems to be in the Company’s best interest. This may result in a substantial reduction of the scope of existing and planned operations.

The Company’s continuing operations are dependent upon its ability to raise capital and generate cash flow. At January 31, 2024, the Company had a working capital deficiency of \$1,204,043 (October 31, 2023 – working capital deficiency of \$1,145,268), had not generated sufficient revenues to cover expenses and had an accumulated deficit of \$12,189,761 (October 31, 2023 - \$12,130,703). The continuation of the Company as a going concern is dependent on generating future cash flows and obtaining necessary financing to fund ongoing operations.

These financial statements do not reflect any adjustments, which could be material, to the carrying values of assets and liabilities, which may be required should the Company be unable to continue as a going concern.

## GENIX PHARMACEUTICALS CORPORATION

Notes to Condensed Interim Financial Statements

(Expressed in Canadian dollars)

For the three months ended January 31, 2024 and 2022

---

### 2. BASIS OF PRESENTATION

#### Statement of compliance

The financial statements of the Company have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and Interpretations issued by the International Financial Reporting Interpretations Committee ("IFRIC").

#### Basis of presentation

The financial statements have been prepared on a historical cost basis except for certain financial assets measured at fair value. All dollar amounts presented are in Canadian dollars unless otherwise specified.

#### Significant accounting judgements and estimates

##### *Significant accounting judgments*

##### Going concern

The ability to continue as a going concern as discussed in Note 1 requires a degree of judgment and is assessed at the end of each reporting period. Considerations taken into account include available information about the future including the availability of financing and revenue projection, as well as current working capital balance and future commitments of the Company.

##### Impairment

Assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts exceed their recoverable amounts and also at each reporting period. Recoverability is dependent upon assumptions and judgments regarding market conditions, cost of operations and sustaining capital requirements. If an asset is impaired, judgment is required in assessing the available information in regard to the amount of impairment.

##### *Significant accounting estimates*

##### Share-based payments

Estimating the fair value for granted stock options and compensatory warrants requires determining the most appropriate valuation model which is dependent on the terms and conditions of the grant. The estimate also requires determining the most appropriate model including the expected life of the option or warrant, volatility, dividend yield, and rate of forfeitures and making assumptions about them.

##### Carrying values of intangible assets

The Company assesses the carrying value of its intangible assets annually or more frequently if warranted by a change in circumstances. If it is determined that carrying values of assets cannot be recovered, the unrecoverable amounts are charged against current earnings. Recoverability is dependent upon assumptions and judgments regarding market conditions, cost of operations and sustaining capital requirements. Other assumptions used in the calculation of recoverable amounts are discount rates and future cash flows. A material change in the assumptions may significantly impact the potential impairment of these assets.

##### Impairment

Assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts exceed their recoverable amounts and also at each reporting period. The assessment of the carrying amount often requires estimates and assumptions such as discount rates, future capital requirements and future operating performance.



## GENIX PHARMACEUTICALS CORPORATION

Notes to Condensed Interim Financial Statements

(Expressed in Canadian dollars)

For the three months ended January 31, 2024 and 2022

---

### 2. BASIS OF PRESENTATION (continued...)

*Significant accounting estimates (continued...)*

#### Useful lives of intangible assets

Estimates of the useful lives of intangible assets are based on the period over which the assets are expected to be available for use. The estimated useful lives are reviewed annually and are updated if expectations differ from previous estimates due to technical or commercial obsolescence, and legal or other limits on the use of the relevant assets. In addition, the estimation of the useful lives of the relevant assets may be based on internal technical evaluation and experience with similar assets. It is possible, however, that future results of operations could be materially affected by changes in the estimates brought about by changes in the factors mentioned above. The amounts and timing of recorded expenses for any period would be affected by changes in these factors and circumstances.

#### Recovery of deferred tax assets

Judgment is required in determining whether deferred tax assets are recognized on the statement of financial position. Deferred tax assets, including those arising from un-utilized tax losses require management to assess the likelihood that the Company will generate taxable earnings in future years, to utilize recognized deferred tax assets. Estimates of future taxable income are based on forecasted cash flows from operations and the application of existing tax laws in each jurisdiction. To the extent that future cash flows and taxable income differ significantly from estimates, the ability of the Company to realize the net deferred tax assets recorded at the reporting date could be impacted. Additionally, future changes in tax laws in the jurisdictions in which the Company operates could limit the ability of the Company to obtain tax deductions in future years.

#### Leases

The lease term is estimated by considering the facts and circumstances that can create an economic incentive to exercise an extension option, or not exercise a termination option by assessing relevant factors such as profitability and operations. Extension option (or options after termination options) are only included in the lease term in if the lease is reasonably certain to be included (or not terminated). The assessment of the lease term is reviewed if a significant event or significant change in circumstance occurs, which affects this assessment that is within the control of the lessee. The Company estimates the incremental borrowing rate used to measure its lease liability for each lease contract. This includes estimation in determining the asset specific security impact.

### 3. SIGNIFICANT ACCOUNTING POLICIES

These condensed interim financial statements have been prepared on the basis of accounting policies and methods of computation consistent with those applied in the Company's annual financial statements for the year ended October 31, 2023.

#### **Upcoming standards**

There are no upcoming standards that will have a material impact on the Company's financial statements.

### 4. Inventory

	January 31, 2024	October 31, 2023
Raw materials	\$ 9,204	\$ 7,289
Finished goods	151,811	151,824
Total inventory	\$ 161,015	\$ 159,113

## GENIX PHARMACEUTICALS CORPORATION

Notes to Condensed Interim Financial Statements

(Expressed in Canadian dollars)

For the three months ended January 31, 2024 and 2022

### 5. Intellectual Property

	Ophthalmic Drugs	Sucanon®	Rechlor®	Flu-X®	Levothyroxine Sodium	Total
<b>Cost:</b>						
Balance, October 31, 2022	\$ 4,535,000	100,000	250,000	100,000	440,562	\$ 5,425,562
No activity for the year	-	-	-	-	-	-
Balance, October 31, 2023	4,535,000	100,000	250,000	100,000	440,562	5,425,562
No activity for the period	-	-	-	-	-	-
<b>Balance, January 31, 2024</b>	<b>4,535,000</b>	<b>100,000</b>	<b>250,000</b>	<b>100,000</b>	<b>440,562</b>	<b>5,425,562</b>
<b>Accumulated amortization:</b>						
Balance, October 31, 2022	1,233,768	28,082	70,206	26,055	68,015	1,426,126
Amortization during the year	453,500	10,000	25,000	10,000	44,056	542,556
Impairment	2,847,731	61,917	154,793	63,944	328,490	3,456,875
Balance, October 31, 2023	4,534,999	99,999	249,999	99,999	440,561	5,425,557
No activity for the period	-	-	-	-	-	-
<b>Balance, January 31, 2024</b>	<b>4,534,999</b>	<b>99,999</b>	<b>249,999</b>	<b>99,999</b>	<b>440,561</b>	<b>5,425,557</b>
<b>Net book value:</b>						
As at October 31, 2023		1	1	1	1	5
<b>As at January 31, 2024</b>	<b>\$ 1</b>	<b>\$ 1</b>	<b>\$ 1</b>	<b>\$ 1</b>	<b>\$ 1</b>	<b>5</b>

#### Ophthalmic Drugs

On February 14, 2020, the Company completed the acquisition of 30 World Health Organization approved ophthalmic drugs and product dossiers from Canagen Pharmaceuticals Inc. ("Canagen") in exchange for 15,000,000 common shares. These shares were issued at a deemed price of \$0.30 per share for a total of \$4,535,000 based on the fair value of the asset at the time of acquisition.

#### Sucanon® and Rechlor®

On January 10, 2020 the Company entered into an acquisition agreement with Canagen, to purchase sole and exclusive distribution, sales and marketing rights and interest for Canada, (excluding intellectual property rights) for an initial term of ten years to two nutraceutical products under the brand names Sucanon® and Rechlor®.

Sucanon® is a herbal health supplement that has been shown in clinical and scientific studies to help manage blood sugar levels and improve insulin sensitivity in non-insulin dependent adults.

Rechlor® is a patented dietary supplement that has been shown to support kidney health in several clinical and scientific studies. Made with all-natural, sugar-free ingredients, Rechlor® is a powerful antioxidant that is sourced from natural ingredients.

Genix has agreed to pay Canagen \$100,000 for the Sucanon® rights and \$250,000 for the Rechlor® rights, for a total of \$350,000 ("Purchase Price") to be paid in tranches as follows:

#### **SUCANON®**

	Amount	Due Date	Status
Principal payment	\$ 25,000	July 22, 2020	Paid
2nd payment	35,000	December 31, 2024	Outstanding
3rd payment	40,000	December 31, 2024	Outstanding
<b>Total purchase price</b>	<b>\$ 100,000</b>		

#### **RECHLOR®**

	Amount	Due Date	Status
Principal payment	\$ 62,500	July 22, 2020	Paid
2nd payment	87,500	December 31, 2024	Outstanding
3rd payment	100,000	December 31, 2024	Outstanding
<b>Total purchase price</b>	<b>\$ 250,000</b>		

## GENIX PHARMACEUTICALS CORPORATION

Notes to Condensed Interim Financial Statements

(Expressed in Canadian dollars)

For the three months ended January 31, 2024 and 2022

### 5. Intellectual Property (continued...)

The second and third payments due for both Sucanon® and Rechlor® were extended to June 30, 2023 as agreed to by both parties.

If the Company fails to make the 2nd payment by the extended deadline of June 30, 2022, it has agreed to pay Canagen interest in the amount equal to 12% of the outstanding amount from the second anniversary of the closing date, plus a penalty in the amount of 1.5%; and

If the Company fails to make the 2nd or 3rd payments of the Purchase Price for a period of longer than three (3) months from the extended due dates, all rights, including all Natural Product Numbers (“NPNs”) issued to Genix by Health Canada or granted to the Company by Canagen shall be immediately transferred and assigned to Canagen. During the year ended October 31, 2022, the Company has been awarded a Natural Product Number (“NPN”) by Health Canada permitting Sucanon® to be sold throughout Canada.

#### Flu-X®

On March 24, 2020, the Company entered into an agreement, with Canagen to purchase the sole and exclusive global distribution, sales and marketing rights and interest for Flu-X®, a novel and proprietary, anti-viral, anti-flu and common colds coronavirus oral and spray herbal product. The Company acquired the global rights for a term of ten years, extendable by mutual agreement, by making cash payments to Canagen totaling \$100,000, comprising \$25,000 paid within four months of closing, and \$75,000 within the first anniversary thereafter. Canagen has been paid the first installment of \$25,000. The second installment of \$75,000 was extended and is due on June 30, 2023.

#### Levothyroxine Sodium (Synthroid®)

On March 26, 2021, the Company entered into an exclusive Canadian licensing and supply agreement (the “Agreement”) with Acme Generics LLP (“ACME”) for the manufacture, sale, marketing and distribution of Canada’s first available generic version of Levothyroxine sodium (Synthroid®). The Company will pay ACME a total licensing fee of \$433,440 (US \$350,000) (the “Transaction”) for the exclusive Canadian rights which includes eleven dosages of Levothyroxine sodium. ACME will assist the Company and its regulatory consultants to file Abbreviated New Drug Submissions (ANDS) with Health Canada to obtain regulatory approvals for legal sale of the drugs in Canada.

The first payment of \$108,360 (US \$87,500) was paid upon signing the agreement. The second payment of \$108,360 (US \$87,500) is payable upon completion of the satisfactory review and GAP analysis of the drug dossier by the Company’s regulatory consultants and the consultants’ written positive opinion of the dossier being acceptable by Health Canada. The third payment of \$216,720 (US \$175,000) is payable upon Health Canada’s approval and issuance of the Notice of Compliance (NOC), marketing authorization for Canada and Health Canada’s issuance of Drug Identification Numbers (DINs) for the products. The initial term of the Agreement is for an eight-year period from the date of product approval by Health Canada, which is expected to take between 18-24 months, and will renew automatically for two year terms thereafter. During the year ended October 31, 2022, the Company made a payment of \$54,994 (US \$43,750) towards the second payment and paid the remaining balance of the second payment of US \$43,750 in the current quarter.

For the year ended October 31, 2023, the Company has written down the carrying cost of its Intellectual Property to \$5 due to a lack of demand and sales of the products. The Company recognized total impairment of \$3,456,875 as the carrying values of the assets exceeded their recoverable amounts due to forecasted revenues not materializing for the year ended October 31, 2023 and subsequently.

The remaining payment obligations for Sucanon®, Rechlor®, Flu-X® and Levothyroxine sodium are summarized below:

	Sucanon®		Rechlor®		Flu-X®		Levothyroxine Sodium		Total	
Current portion (due in less than 12 months)	\$	75,000	\$	187,500	\$	75,000	\$	234,448	\$	571,948
Long term portion		-		-		-		-		-
	\$	75,000	\$	187,500	\$	75,000	\$	234,448	\$	571,948

\*\* Note that the payments due for Sucanon®, Rechlor® and Flu-X® are payable to Canagen, a related party with a common director and President of the Company.

**GENIX PHARMACEUTICALS CORPORATION**

Notes to Condensed Interim Financial Statements

*(Expressed in Canadian dollars)*

For the three months ended January 31, 2024 and 2022

**6. Website**

	<b>Website</b>	
<b>Cost:</b>		
Balance, October 31, 2022	\$	11,339
Additions for the year		-
Balance, October 31, 2023		11,339
No activity during the year		-
Balance, January 31, 2024		11,339
<b>Accumulated amortization:</b>		
Balance, October 31, 2022		2,305
Amortization during the year		1,132
Balance, October 31, 2023		3,437
Amortization during the year		283
Balance, January 31, 2024	\$	3,720
<b>Net book value:</b>		
As at October 31, 2023		7,902
<b>As at January 31, 2024</b>	<b>\$</b>	<b>7,619</b>

**7. Trade and Other Payables**

The Company's accounts payable and accrued liabilities are as follows:

	<b>January 31,</b>		<b>October 31,</b>	
	<b>2024</b>		<b>2023</b>	
Trade payables	\$	<b>280,784</b>	\$	249,054
Accrued liabilities		<b>15,000</b>		20,000
	<b>\$</b>	<b>295,784</b>	<b>\$</b>	269,054

**8. Loans from Shareholders**

	<b>January 31,</b>		<b>October 31,</b>	
	<b>2024</b>		<b>2023</b>	
Shareholder loans	\$	<b>575,387</b>	\$	511,525
	<b>\$</b>	<b>575,387</b>	<b>\$</b>	511,525

The loans are from two shareholders who are also directors bear interest at 10% per annum and are repayable at the earlier of one year or the Company's next private placement. There was no collateral pledged against these loans. The amount of shareholder loans outstanding includes accrued interest of \$80,532 (2023 - \$49,279).

## GENIX PHARMACEUTICALS CORPORATION

Notes to Condensed Interim Financial Statements

(Expressed in Canadian dollars)

For the three months ended January 31, 2024 and 2022

### 9. Related Party Transactions

During the three months ended January 31, 2024, the Company entered into the following transactions with related parties:

- Paid or incurred consulting and management fees of \$1,500 (2023 - \$1,000) to a company controlled by an officer of the Company. As at January 31, 2024, \$nil (2023 - \$nil) was included in trade and other payables for consulting fees.
- Paid or incurred in consulting fees of \$9,000 (2023 - \$26,000) to an officer of the Company. As at January 31, 2024, \$26,326 (2023 - \$26,322) was included in trade and other payables for management fees and reimbursement of expenses.
- Paid or incurred lease payments of \$3,000 (2023 - \$3,000) to a company that is owned by an officer and director of the Company (see Note 10). As at January 31, 2024, \$18,480 (2023 \$5,880) was included in trade and other payables.
- As at January 31, 2024, the Company owed \$337,500 (2023 - \$337,500) to a company that is owned by a director of the Company that was included in obligation liability (see Note 4). The Company also owed \$134,667 (2023 - \$142,201) that was included in trade and other payables for expenses incurred on behalf of the Company.
- As at January 31, 2024, the Company owed \$293,968 (2023 - \$161,410) to a director of the Company for shareholder loans. The Company also owed \$42,294 (2023 - 8,246) in accrued interest and penalties (see Note 8). The Company also owed \$15,183 (2023 - \$15,183) that was included in trade and other payables for expenses incurred on behalf of the Company.
- As at January 31, 2023, the Company owed \$281,419 (2023 - \$153,035) to an officer and director of the Company for shareholder loans. The Company also owed \$38,238 (2023 - \$ 6,865) in accrued interest and penalties (see Note 8). The Company also owed \$9,807 (2023 - \$9,493) that was included in trade and other payables for expenses incurred on behalf of the Company.

All related party amounts were incurred in the normal course of operations. All amounts, except for loans from shareholders and obligations, bear no interest and have no fixed terms of repayment.

### 10. Share Capital and Reserves

#### Authorized Share Capital - Unlimited common shares without par value

#### Issued Share Capital

	Number of shares	Share capital - gross	Share issue - costs	Share capital - net
Balance, October 31, 2023	59,224,131	\$ 9,745,699	\$ 44,937	\$ 9,700,762
No activity during the year	-	-	-	-
Balance, October 31, 2024	59,224,131	9,745,699	44,937	9,700,762
No activity during the period	-	-	-	-
<b>Balance, January 31, 2024</b>	<b>59,224,131</b>	<b>\$ 9,745,699</b>	<b>\$ 44,937</b>	<b>\$ 9,700,762</b>

**GENIX PHARMACEUTICALS CORPORATION**

Notes to Condensed Interim Financial Statements

*(Expressed in Canadian dollars)*

For the three months ended January 31, 2024 and 2022

**10. Share Capital and Reserves (continued...)****Warrants**

A summary of the warrant activities is as follows:

	Number of warrants	Weighted average exercise price
Balance, October 31, 2022	3,354,945 \$	0.30
No activity during the year	-	0.30
Balance, October 31, 2023	3,354,945	0.30
No activity during the period	-	-
<b>Balance, January 31, 2024</b>	<b>3,354,945 \$</b>	<b>0.30</b>

The following share purchase warrants were outstanding as at January 31, 2024:

Expiry date	Number of warrants	Exercise price	Remaining contractual life (years)
July 24, 2025	2,101,612	0.30	1.73
August 13, 2025	1,253,333	0.30	1.79
	<b>3,354,945 \$</b>	<b>0.30</b>	<b>1.75</b>

The weighted average life of warrants outstanding as at January 31, 2023 is 1.00 year. The expiry date of the warrants was extended by 18 months on February 6, 2024.

**Stock Options**

The Company has a fixed stock-based compensation plan (the "Plan") providing for the grant of stock options to purchase a maximum of 10% of the issued and outstanding common shares outstanding.

*During the three months ended January 31, 2024:*

- a. There was no stock option activity during the period.

*During the year ended October 31, 2023:*

- b. There was 1,100,000 stock options cancelled.

A summary of the stock options activities is as follows:

	Number of options	Weighted average exercise price
Balance, October 31, 2022	5,900,000 \$	0.12
Cancelled	(1,100,000)	-
Balance, October 31, 2023	4,800,000	0.12
No activity for the period	-	-
<b>Balance, January 31, 2024</b>	<b>4,800,000 \$</b>	<b>0.12</b>

## GENIX PHARMACEUTICALS CORPORATION

Notes to Condensed Interim Financial Statements

(Expressed in Canadian dollars)

For the three months ended January 31, 2024 and 2022

### 10. Share Capital and Reserves (continued...)

#### Stock Options (continued...)

The following table summarizes information about the options outstanding and exercisable at January 31, 2024:

Expiry date	Options outstanding	Options exercisable	Exercise price	Remaining contractual life (years)
August 5, 2025	1,400,000	1,400,000	\$ 0.12	1.51
December 14, 2025	150,000	150,000	\$ 0.12	1.87
December 15, 2025	400,000	400,000	\$ 0.12	1.87
March 22, 2026	2,850,000	2,850,000	\$ 0.12	2.14
	<b>4,800,000</b>	<b>4,800,000</b>		<b>1.93</b>

The weighted average life of stock options outstanding as at January 31, 2025 is 1.93 years.

#### Loss per share

The effect of dilutive securities including options and warrants has not been shown as the effect of all such securities is anti-dilutive.

### 11. Segmented Information

#### Operating segment:

The Company operated in one operating segment consisting of nutraceutical and pharmaceutical products.

#### Geographic segments:

The Company operated only in Canada for the three months ended January 31, 2024 and 2023.

### 12. Financial Instruments and Risk Management

The fair value of the Company's receivables and payables approximate their carrying value, due to their short-term nature. The Company's cash is measured at fair value under the fair value hierarchy based on level one quoted prices in active markets for identical assets or liabilities.

The Company's financial instruments are exposed to certain financial risks, including, credit risk, liquidity risk, interest rate risk and price risk, and currency risk.

#### Credit

Credit risk is the risk of an unexpected loss if a customer or third party to a financial instrument fails to meet its contractual obligations.

The Company is exposed to credit risk on its cash and receivables. The Company limits its exposure to credit risk by holding its cash in large Canadian financial institutions. The Company does not have any asset-backed commercial paper. The Company performs ongoing credit evaluations of its trade receivables but does not require collateral. The Company establishes an allowance for doubtful accounts based on the credit risk applicable to particular customers and historical data. The Company maintains cash deposits with Schedule A financial institutions, which from time to time may exceed federally insured limits. The Company has not experienced any significant credit losses and believes it is not exposed to any significant credit risk.

## **GENIX PHARMACEUTICALS CORPORATION**

Notes to Condensed Interim Financial Statements

*(Expressed in Canadian dollars)*

For the three months ended January 31, 2024 and 2022

---

### **12. Financial Instruments and Risk Management (continued...)**

#### **Liquidity risk**

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due.

The Company manages liquidity risk through its capital management as outlined in Note 15. The Company's ability to continue as a going concern is dependent on management's ability to raise required funding through future equity issuances and through short-term borrowing. The Company manages its liquidity risk by forecasting cash flows from operations and anticipating any investing and financing activities. Management and the Board of Directors are actively involved in the review, planning and approval of significant expenditures and commitments. As at January 31, 2023, management is actively reviewing its options to raise additional working capital for the Company to support ongoing operations and meet its liabilities as they fall due.

#### **Market risk**

Market risk is the risk of loss that may arise from changes in market factors such as interest rates, commodity and equity prices, and foreign exchange rates.

#### **Interest rate risk**

Interest rate risk is the risk the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company does not hold any financial liabilities with variable interest rates. The Company does maintain bank accounts which earn interest at variable rates but it does not believe it is currently subject to any significant interest rate risk, as these variable interest rates are minimal.

#### **Price risk**

Price risk is the risk associated with equity prices. The Company closely monitors equity prices to determine the appropriate course of action to be taken by the Company.

#### **Foreign exchange risk**

The Company's functional and reporting currency is the Canadian dollar. The Company is exposed to foreign currency risk from fluctuations in foreign exchange rates and the degree of volatility in these rates due to the timing of their trade payable and obligation balances. The risk is mitigated by timely payment of creditors and monitoring of foreign exchange fluctuations by management. As at January 31, 2024, the Company did not use derivative instruments to hedge its exposure to foreign currency risk.

### **13. Capital Disclosure and Management**

The Company's capital management policy is to maintain a strong, but flexible capital structure that optimizes the cost of capital, creditor and market confidence while sustaining the future development of the business.

The Company manages its capital structure and makes adjustments to it in light of changes in economic conditions. The Company's capital structure includes shareholders' deficiency as at January 31, 2024 of \$1,196,419 (As at December 31, 2023 – deficiency of \$1,137,361). In order to maintain or adjust the capital structure, the Company may from time to time issue shares, seek additional debt financing and adjust its capital spending to manage current and projected debt levels. The Company is not subject to externally imposed capital requirements other than as noted above. There were no changes to the Company's approach to capital management during the three months ended January 31, 2024.

### **14. Subsequent Event**

Subsequent to January 31, 2024, two directors loaned a total of \$80,000 to the Company to fund ongoing operations. The loans carry an interest rate of 10% per annum. There was no collateral pledged against these loans.